Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Today Montana.
Press releases published on October 27, 2025
Fungushead Launches Veteran ‘Angel’s Wing Scholarship’ and Reaffirms Microscopy-Only Standards as California Accelerates Psychedelic Research (AB 1103)
DENVER, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Fungushead, a microscopy and mycology education company, today announced two key initiatives — the launch of its Angel’s Wing Scholarship for U.S. military veterans and a reaffirmed microscopy-only policy — as …
Health Canada Approval of Lecanemab Offers New Hope for Ontarians Living with Alzheimer’s Disease
The Alzheimer Society of Ontario calls for immediate system investments to support access to the newly approved dementia treatment TORONTO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- The Alzheimer Society of Ontario applauds the approval of Lecanemab by Health …
Health legislation update brings breast cancer care into the modern age
Arlington Heights, Ill, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Insurance denials and delays for breast and chest wall reconstruction after cancer will become a thing of the past with passage of the Advancing Women's Health Coverage Act (AWHCA). The American …
LifeLabs Care Packages Bring Comfort to Children with Cancer at POGO Satellite Clinics
Toronto, Ontario, Oct. 27, 2025 (GLOBE NEWSWIRE) -- A childhood cancer diagnosis changes everything for a family. To help provide comfort during this difficult time, LifeLabs has donated customized care packages and treasure baskets to support children …
Protext Mobility, Inc. (OTC: TXTM) Ignites Next Phase of Growth with Investor Relations Presentation Initiative — Setting the Stage for a New Era of Transparency and Acceleration
NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Protext Mobility, Inc. (OTC: TXTM), an emerging powerhouse in botanical-based biotechnology, today announced the upcoming launch of its Investor Relations (IR) Presentation and Microsite — a major step in the …
Gastroparesis Market Poised for Extraordinary Growth at a 21.9% CAGR in the US by 2034 Due to the Launch of Novel MoAs Such as NK-1R Antagonists, 5-HT4 Receptor Agonists, D2 Receptor Antagonists, and Others | DelveInsight
New York, USA, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Gastroparesis Market Poised for Extraordinary Growth at a 21.9% CAGR in the US by 2034 Due to the Launch of Novel MoAs Such as NK-1R Antagonists, 5-HT4 Receptor Agonists, D2 Receptor Antagonists, and Others …
Hapbee Appoints New Leaders to Accelerate Women’s Wellness Through Frequency Healing Technology
VANCOUVER, British Columbia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Hapbee Technologies Inc. (“Hapbee” or the “Company”) (TSXV: HAPB | OTCQB: HAPBF | FWB: HA1) — Hapbee Technologies Inc. (“Hapbee”), the pioneer in frequency-based digital wellness technology, …
Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences
Saint-Herblain (France), October 27, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and participate in 1-on-1 meetings with institutional investors at upcoming …
Valneva fera des présentations et rencontrera les investisseurs lors de conférences aux États-Unis et en Europe
Saint-Herblain (France), le 27 octobre 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que des membres de son équipe dirigeante feront des présentations et participeront à des rendez-vous …
Smith+Nephew comparative study1 shows PICO◊ sNPWT (-80 mmHg) delivers superior performance in relation to wound dehiscence and reduces healthcare costs across cardiovascular and orthopedic surgery versus PrevenaTM -125 mmHg sNPWT
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces findings from a newly published, first-of-its-kind comparative study of single-use negative pressure wound therapy (sNPWT) devices in orthopedic and cardiovascular …
MAIA Biotechnology Presents Trial in Progress Poster at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
First five patients in Part C (expansion) of THIO-101 Phase 2 clinical trial enrolled in Taiwan and Turkey CHICAGO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical …
Health legislation update brings breast cancer care into the modern age
Arlington Heights, Ill, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Insurance denials and delays for breast and chest wall reconstruction after cancer will become a thing of the past with passage of the Advancing Women's Health Coverage Act (AWHCA). The American …
Prenetics Announces Oversubscribed Approximately $48 Million Equity Offering with Potential for $216 Million in Total Proceeds to Fuel IM8’s Global Expansion and Bitcoin Treasury Strategy
Distinguished Investor Group Includes Kraken, American Ventures, Exodus (NYSE: EXOD), XtalPi (2228.hk), DL Holdings (1709.hk) GPTX by Jihan Wu and Leading Institutions World No. 1 and 4-time Grand Slam champion Aryna Sabalenka expands her stake in …
A New Era for Dermatology PAs and NPs Begins with PANP360
Plano, Texas, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Dermsquared is proud to announce the launch of PANP360, a reimagined hub built entirely for dermatology physician assistants and nurse practitioners. More than a website, PANP360 marks the start of a movement …
Prenetics Announces $48.0 Million Equity Offering to Fuel IM8’s Global Expansion and Bitcoin Treasury Strategy
CHARLOTTE, N.C., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading health sciences company, today announced the successful pricing of a best efforts public offering (the “Offering”) of (i) 2, …
Clearmind Medicine Appoints Mary-Elizabeth Gifford as Chief of Global Impact to Advance US Partnerships and Governmental Engagement
Vancouver, Canada, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel neuroplastogens-derived therapeutics to …
Longeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR’s BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect
Laromestrocel is a proprietary, scalable, allogeneic cellular therapy being evaluated to improve the clinical outcomes of children with HLHS Full enrollment achieved for pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential …
Philips introduces industry-first cath lab integration that automatically synchronizes pre-operative CT with C-arm movement, paving the way for CT-guided PCI
October 27, 2025 New integration of Philips Advanced Visualization Workspace* with the Azurion image-guided therapy platform automatically synchronizes CT images with C-arm movement, supporting workflow …
Curia invierte 4 millones de dólares para mejorar la fabricación de APIs estériles
ALBANY, Nueva York, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Curia Global, Inc. (Curia), una organización líder mundial en investigación, desarrollo y fabricación, anunció hoy la finalización de una inversión de 4 millones de dólares para actualizar sus dos salas …